Condition: NAFLD (Non-alcoholic Fatty Liver Disease) · NASH (Nonalcoholic Steatohepatitis) · Sponsor: Tasly Biopharmaceuticals Co., Ltd.
This is a randomized, double-blind, multicenter, placebo-controlled, multiple-dose escalating clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity profile of B1344 in patients with NAFLD. Additionally, the trial will conduct preliminary observations on the efficacy of B1344, aiming to provide early proof of concept for B1344 as a therapeutic agent for NASH.
This description comes directly from the study's public registry record.
Lai Wei · 13601281862 · weilai@mail.tsinghua.edu.cn
Always discuss trial participation with your own doctor first.
| Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University | Beijing, Beijing Municipality, China | Recruiting |
| Nanfang Hospital, Southern Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sinopharm Tongmei General Hospital | Datong, Shanxi, China | Not Yet Recruiting |
| The First Affiliated Hospital to Nankai University | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
| The First Affiliated Hospital to Wenzhou Medical University | Wenzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07128797